
Actuate Therapeutics, Inc. (NASDAQ:ACTU – Free Report) – Analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Actuate Therapeutics in a research report issued on Monday, November 16th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.57) per share for the year, up from their prior forecast of ($0.61). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Actuate Therapeutics’ current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Actuate Therapeutics’ Q4 2026 earnings at ($0.07) EPS, Q1 2027 earnings at ($0.06) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.05) EPS, FY2027 earnings at ($0.22) EPS, FY2028 earnings at ($0.25) EPS, FY2029 earnings at $0.04 EPS and FY2030 earnings at $0.52 EPS.
Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04.
Get Our Latest Stock Analysis on Actuate Therapeutics
Actuate Therapeutics Stock Performance
Shares of NASDAQ:ACTU opened at $0.21 on Wednesday. Actuate Therapeutics has a twelve month low of $0.17 and a twelve month high of $7.90. The business has a fifty day moving average of $0.58 and a 200-day moving average of $1.83.
Insider Activity at Actuate Therapeutics
In other news, CEO Daniel M. Schmitt bought 140,844 shares of the stock in a transaction dated Wednesday, October 28th. The stock was bought at an average cost of $0.35 per share, with a total value of $49,295.40. Following the purchase, the chief executive officer owned 442,560 shares of the company’s stock, valued at approximately $154,896. This represents a 46.68% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 57.98% of the company’s stock.
Hedge Funds Weigh In On Actuate Therapeutics
Several large investors have recently made changes to their positions in ACTU. ABS Direct Equity Fund LLC raised its holdings in Actuate Therapeutics by 46.4% during the 2nd quarter. ABS Direct Equity Fund LLC now owns 73,186 shares of the company’s stock worth $112,000 after purchasing an additional 23,186 shares during the last quarter. HighTower Advisors LLC acquired a new position in Actuate Therapeutics during the 2nd quarter valued at about $56,000. Susquehanna International Group LLP acquired a new position in Actuate Therapeutics during the 2nd quarter valued at about $43,000. Palogic Value Management L.P. bought a new position in shares of Actuate Therapeutics in the 2nd quarter valued at about $153,000. Finally, ABS Investment Management LLC bought a new position in shares of Actuate Therapeutics in the 2nd quarter valued at about $111,975.
Key Stories Impacting Actuate Therapeutics
Investors following ACTU have been watching these stories:
- Positive Sentiment: Daily oral elraglusib produced up to 77% tumor-growth inhibition as a single treatment in an aggressive melanoma model. Researchers also reported immune changes associated with antitumor activity, and greater activity at higher drug exposures. The company says the results support starting a Phase 1/2 trial in the first quarter of 2027. Article: Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model
- Positive Sentiment: HC Wainwright maintained a Buy rating and raised several earnings estimates for 2026–2028, including lowering projected losses for 2027 and 2028. These revisions may offer some support, although they are analyst forecasts rather than company results. Actuate Therapeutics analyst and company information
- Negative Sentiment: HC Wainwright also cut its 2029 and 2030 earnings forecasts, tempering the otherwise improved estimates. The melanoma data are preclinical, so efficacy and safety in people remain unproven; investors may need to wait for trial progress for clinical validation.
Actuate Therapeutics Company Profile
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing treatments for cancer. Its research focuses on elraglusib, an investigational small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β), a target involved in processes that can affect tumor growth and the tumor microenvironment. The company is evaluating elraglusib in clinical trials, including in combination with chemotherapy for patients with pancreatic cancer and other solid tumors. Elraglusib is not an approved medicine, and Actuate does not currently have marketed products.
Recommended Stories
- Five stocks we like better than Actuate Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Actuate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actuate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
